SCHEMBL7252008

SCHEMBL7252008

COC(=O)c1cc(CBr)cc(-c2ccccc2)c1.c1ccc(P(c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 2/20 0.44
CYP4A11 Q02928 2/20 0.44
LMNA P02545 1/20 0.42
HPGD P15428 1/20 0.42
EGFR P00533 1/20 0.42
TSHR P16473 1/20 0.41
HIF1A Q16665 1/20 0.41
CA1 P00915 2/20 0.40
CA2 P00918 2/20 0.40
CA12 O43570 1/20 0.40
CA9 Q16790 1/20 0.40
AXL P30530 1/20 0.40
LOXL2 Q9Y4K0 1/20 0.40
MAPT P10636 1/20 0.39
RAB9A P51151 1/20 0.39
GABRG2 P18507 1/20 0.38
GABRB3 P28472 1/20 0.38
GABRA5 P31644 1/20 0.38
GABRA3 P34903 1/20 0.38
PTGS2 P35354 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7240867 0.92 CYP4F2 (0.50) CYP4F2CYP4A11LMNAHPGDEGFR
SCHEMBL9875461 0.83 LOXL2 (0.56) CYP4F2CYP4A11LMNAHPGDTSHR
SCHEMBL197540 0.81 TSHR (0.53) CYP4F2CYP4A11HPGDTSHRCA1
SCHEMBL7824090 0.79 EGFR (0.52) CYP4F2CYP4A11LMNAHPGDEGFR
SCHEMBL4257678 0.77 TSHR (0.63) LMNAHPGDEGFRTSHRCA1
SCHEMBL7823750 0.77 TSHR (0.63) LMNAHPGDEGFRTSHRHIF1A
SCHEMBL28992722 0.76 LOXL2 (0.46) CYP4F2CYP4A11LMNAHPGDEGFR
SCHEMBL10484479 0.76 TSHR (0.57) LMNAHPGDEGFRTSHRHIF1A
SCHEMBL2409454 0.75 CYP4F2 (0.42) CYP4F2CYP4A11LMNAHPGDTSHR
SCHEMBL4652534 0.75 CA12 (0.52) CYP4F2CYP4A11LMNAHPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030220495-A1 Inhibitors of farnesyl protein transferase ZENECA LIMITED AND ZENECA PHARMA S.A. 2003-11-27 US disclosed
US-6414145-B1 TREATING CANCER AND NEUROFIBROMATOSIS ZENECA LIMITED (GB) 2002-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220495-A1 Inhibitors of farnesyl protein transferase KRAS, FNTA, FNTB CYP4F2 115/4885CYP4A11 219/4885LMNA 2982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.